NT Mobile Menu

Search form


AAN 2016

AAN 2016

This year's American Academy of Neurology annual meeting takes place April 15-21, 2016 in Vancouver, British Columbia.

AAN 2016

Can we see changes in the brain that correspond to cognitive difficulties? Research presented at AAN 2016 offers compelling information.

In a proof-of-concept study, 25 patients were exposed to a dose-escalating infusion of SAGE-547 to evaluate the drug’s effect on essential tremor.

Researchers used simulations to predict the outcomes of epilepsy patients with partial-onset seizures converting to Aptiom monotherapy (800 mg QD).

Research leading up to the ongoing phase 3 trial of SAGE-547, a potential drug for super-refractory status epilepticus, was presented at AAN 2016.

Do you and your patients with epilepsy agree on treatment decisions? A national survey compares AED attribute preferences of patients and neurologists.

From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.

In addition to Guillain-Barré syndrome, a small study from Brazil discussed Zika virus and a possible tie to another autoimmune disorder at AAN 2016.


Subscribe to AAN 2016 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.